孙维佳， Email: email@example.com
目的：探讨开发以核酸适体KMF2-1a为基础的乳腺癌细胞靶向阿霉素载体的可行性。 方法：应用流式细胞仪检测人乳腺癌MCF-10AT1细胞对核酸适体KMF2-1a及其修饰物（药物载体）的内吞作用；将阿霉素与药物载体相互作用后，用分光光度计检测阿霉素嵌入药物载体的情况。 结果：流式细胞仪检测示，核酸适体KMF2-1a及其修饰物均能被MCF-10AT1细胞特异内吞；分光光度仪检测示，阿霉素可成功嵌入至药物载体中。 结论：核酸适体KMF2-1a能被MCF-10AT1细胞特异内吞，经修饰后有可能作为阿霉素的载体用于乳腺癌的靶向治疗。
Objective: To investigate the feasibility of the development of aptamer KMF2-1a-based doxorubicin carrier that targets breast cancer cells. Methods: The internalization efficacies of aptamer KMF2-1a and its modified product (drug carrier) into human breast cancer MCF-10AT1 cells were tested by flow cytometry analysis. The incorporation of doxorubicin into the drug carrier was determined by spectrophotometer analysis after their interaction. Results: Flow cytometry analysis showed that both aptamer KMF2-1a and its modified product could be specifically internalized by MCF-10AT1 cells. Spectrophotometer detection demonstrated that doxorubicin was successfully incorporated into the drug carrier. Conclusion: Aptamer KMF2-1a can be internalized specifically by MCF-10AT1 cells, and it can be potentially used as a doxorubicin carrier after modification for targeted breast cancer therapy.